Skip to main content
    N

    Nurix Therapeutics Inc (NRIX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.73
    -0.75 (-4.84%)

    Market Cap: $1.69B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Nurix Therapeutics Inc (NRIX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Nurix Therapeutics (NRIX) to earn $3.02 per share in the fiscal year ending Nov 30, 2026, on revenue of $744.85M. Of 14 analysts, 13 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Nov 30, 2026 were revised up and 3 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 1.71, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 93% of the ratings.

    RatingAnalystsShare
    Strong Buy535.7%
    Buy857.1%
    Hold17.1%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    14

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a profit to a loss and revenue estimates fall 83.5%.

    Fiscal year ending Nov 30, 2026
    $3.02
    EPS consensus, revenue $744.85M
    Fiscal year ending Nov 30, 2027
    -$1.28
    EPS consensus, revenue $123.22M
    Next report
    Jan 26, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Nov 30, 2026$3.02$2.96 to $3.103$744.85M$704.05M to $785.20M4
    Nov 30, 2027-$1.28-$2.48 to -$0.623$123.22M$58.00M to $200.00M4

    Quarterly Estimates

    The EPS consensus falls from -$0.50 for the quarter ending Nov 30, 2026 to -$0.59 for the quarter ending Feb 28, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Nov 30, 2026-$0.50-$0.79 to $0.0416$36.08M$4.90M to $101.64M15
    Feb 28, 2027-$0.59-$0.59 to -$0.591$15.00M$15.00M to $15.00M1

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 5 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Nov 30, 202603
    Fiscal year ending Nov 30, 202701
    Quarter ending Feb 28, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Nov 30, 2026 has risen 68.7% from $1.79.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Nov 30, 2026$3.02$3.02$3.38$3.38$1.79+69.0%
    Fiscal year ending Nov 30, 2027-$1.28-$1.28-$1.07-$1.07-$1.44N/A
    Quarter ending Feb 28, 2027-$0.59-$0.59-$0.44-$0.44-$0.44N/A

    Frequently Asked Questions About NRIX

    What is the NRIX stock forecast?

    Consensus analyst estimates put Nurix Therapeutics's EPS at $3.02 for the fiscal year ending Nov 30, 2026, on revenue of $744.85M. The consensus rating from 14 analysts is Buy.

    How do analysts rate NRIX stock?

    Of 14 analysts covering Nurix Therapeutics, 5 rate it Strong Buy, 8 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from NRIX next year?

    For the fiscal year ending Nov 30, 2026, the consensus EPS estimate is $3.02, with estimates from $2.96 to $3.10 from 3 analysts. For the fiscal year ending Nov 30, 2027, the consensus EPS estimate is -$1.28, with estimates from -$2.48 to -$0.62 from 3 analysts.

    What revenue do analysts expect from Nurix Therapeutics next year?

    For the fiscal year ending Nov 30, 2026, the consensus revenue estimate is $744.85M, with estimates from $704.05M to $785.20M. For the fiscal year ending Nov 30, 2027, the consensus revenue estimate is $123.22M, with estimates from $58.00M to $200.00M.

    How many analysts cover NRIX?

    14 analysts rate Nurix Therapeutics stock, and 3 analysts estimate its EPS for the fiscal year ending Nov 30, 2026.